This Indicator Says Stocks Are More Expensive Than 2007
By Amber Hestla | March 11, 2019 |

We know dividends are good for income seekers, but the data tells us a completely story -- they're also...

Read Full Story
Analysts Project Big Upside For These 9 Dividend Payers
By Nathan Slaughter | February 19, 2019 |
No One Knows Why This Ratio Works, But It Does...
By | February 15, 2019 |

This number sequence can be used to define support and resistance levels, upside targets, and to identify times when a stock or index is likely to turn. Learn more...

So Much For Doom And Gloom...
By Genia Turanova | February 14, 2019 |

Was the snap-back rally enough to restore trust in the market? It should be. Especially if you have a strong-enough plan in the first place...

High-Yield Bonds Are Still A 'Buy'
By Nathan Slaughter | February 14, 2019 |

Despite a rough finish to 2018, the outlook for high-yield bonds is good. Here's a one-stop way to buy a basket of high-yielders that's worked well for my readers...

5 Fast-Growing Small-Caps To Watch…
By Genia Turanova | February 12, 2019 |

I'm always on the hunt for growth -- and the world of small-cap stocks is always fertile hunting ground. Here are five I've got my eye on right now...

One Of My Favorite "Lifetime Wealth Generators"
By Nathan Slaughter | February 11, 2019 |

This is one of my favorite income stocks. And with a track record like this, it's easy to see why...

Forget About The Winners. Focus On This Instead...
By Jimmy Butts | February 10, 2019 |

Instead of thinking about how many times you were right with your stock picks, it's time to start thinking about what really matters: how much money you're making.

This High-Yield MLP Has Made An Impressive Comeback
By Nathan Slaughter | February 04, 2019 |

One of the largest energy MLPs is bringing in more cash than ever -- but shares are trading for half of what they were a few years ago. Here's why it's one of my top picks...

How We're Betting On A 'Secret Cancer-Beating Weapon'
By Genia Turanova | February 03, 2019 |

New technology is giving doctors is the ability to treat patients with drugs tailored at the molecular level. The implications of this are huge -- here's how I'm planning to invest...

Biotech Megadeal: Is The Stock A 'Buy'?
By Nathan Slaughter | February 01, 2019 |

A $74 billion deal will create a biotech powerhouse. But is this a good deal? And is it worth owning today?

 

Outbrain

 

Outbrain